SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hamon, Y. Articles by Chimini, G. Search for Related Content PubMed PubMed Citation Articles by Hamon, Y. Articles by Chimini, G. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 90 No. 8 (October 15), 1997: pp. 2911-2915 RAPID COMMUNICATION Interleukin-1 Secretion Is Impaired by Inhibitors of the Atp Binding Cassette Transporter, ABC1 By Yannick Hamon, Marie-Françoise Luciani, Frederic Becq, Bernard Verrier, Anna Rubartelli, and Giovanna Chimini From the Centre d'Immunologie INSERM-CNRS de Marseille-Luminy, Marseille, France; the Laboratoire de Neurobiologie Cellulaire du CNRS, Marseille, France; and the Istituto Scientifico Tumori, Genova, Italy.     ABSTRACT Abstract Introduction Methods Results Discussion References The production of interleukin-1 (IL-1), a powerful mediator of inflammation, is tightly regulated at several levels. However, in some pathologic conditions, a pharmacologic treatment is required to control the toxicity of excessive extracellular IL-1. Because of the heavy side effects of most therapies used in IL-1-mediated pathologies, a goal of pharmacologic research is the development of selective anti-IL-1 drugs. We show here that the sulfonylurea glyburide, currently used in the oral therapy of noninsulin dependent diabetes, is an inhibitor of IL-1 secretion from human monocytes and mouse macrophages. Glyburide reduces dramatically the recovery of extracellular 17-kD IL-1 in the absence of toxic effects on the cells and without affecting the synthesis or processing of the IL-1 precursor. IL-1 belongs to the family of leaderless secretory proteins released from the cell by a nonclassical secretory route. In bacteria and yeast Atp binding cassette (ABC) transporters are involved in the secretion of leaderless secretory proteins. Interestingly, glyburide blocks the anion exchanger function of ABC1, a mammalian member of the family of ABC transporters. We thus investigated the involvement of ABC1 in IL-1 secretion, through the analysis of the effects of drugs known to inhibit IL-1 secretion, on the activity of ABC1 and in turn the ability of known inhibitors of ABC1 of blocking IL-1 secretion. Our data show that IL-1 secretion and the function of ABC1 as an anion exchanger are sensitive to the same drugs, therefore suggesting an involvement of the ABC1 transporter in the secretion of leaderless proteins in mammals.     INTRODUCTION Abstract Introduction Methods Results Discussion References INTERLEUKIN-1 (IL-1) is one of the most effective mediators of inflammatory reactions primarily produced by activated monocytes or macrophages. Agents able to impair its production or secretion are therefore of high therapeutic impact. However, unfortunately, the molecular mechanism underlying IL-1 secretion is still obscure.1-3 IL-1 is unique among cytokines, because it is not secreted via the classical exocytic pathway. The lack of a secretory signal peptide hampers its targeting to the endoplasmic reticulum. Large amounts of IL-1, synthesized as a precursor polypeptide of 33 kD, are found in the cytosol, from which the cytokine gains access to the extracellular medium. An additional step is required, because the propolypeptide has to be proteolitycally cleaved by the IL-1 converting enzyme (ICE or caspase I)4,5 to the mature, fully active 17-kD form. ICE-mediated processing and the secretory step appear to occur cotemporally and lead to the exclusive recovery of the mature form in the extracellular medium. The subcellular site where maturation takes place is still an open question. Indeed, whereas ICE and IL-1 colocalize in the cytosol of IL-1-secreting macrophages, the enzymatic activity of ICE is undetectable in the cells.6 Recently, Singer et al7 have proposed on the basis of IEM data that the maturation takes place during the translocation of the precursor (proIL-1) along a transmembrane channel in which active ICE had previously or concomitantly docked. Because similar pathways in prokaryotes and lower eukaryotes use dedicated Atp binding cassette (ABC) translocators, it is reasonable to hypothesize that mammalian ABC transporters act as exporters for IL-1 and other leaderless secretory proteins (see for review Kucher et al8 ). Indeed, ABC transporters can handle a wide variety of substrates and are able to mediate energy-dependent membrane translocation of proteins of fairly large molecular weight such as toxins secreted by gram-negative bacteria.9 We have recently characterized a novel member of this family of protein, ABC1, conserved in mice and humans.10 ABC1 is expressed by macrophages, where it is required during the engulfment of apoptotic corpses.11 When expressed in the heterologous system of Xenopus oocytes, ABC1 behaves as an electroneutral anion exchanger with a characteristic pharmacologic profile.12 We report here on the dramatic inhibitory effect of the sulfonylurea glyburide on IL-1 secretion both in the human and mouse systems. Glyburide happens to be one of the most potent inhibitors of ABC1 activity as an anion transporter in X oocytes and in mouse peritoneal macrophages. Hence, we extended the investigation to other ABC1 blockers and, in turn, to inhibitors of IL-1 secretion13-15 to show that these two effects share a similar pharmacology.     MATERIALS AND METHODS Abstract Introduction Methods Results Discussion References Preparation of mouse peritoneal macrophages. Thioglycollate-elicited peritoneal macrophages (2 mL intraperitoneal injection of thioglycollate medium 4 days previously) were harvested by peritoneal washes from 8- to 12-week-old B6/CBA mice, extensively washed in complete medium (RPMI 1640 supplemented with 10% fetal calf serum [FCS]), and plated at 2 × 105 cells/well in 96-well microtiter plates for secretion studies or at 4 × 105/well in 48-well plates for efflux studies. After incubation at 37°C for 2 hours, nonadherent cells were removed and monolayers were incubated overnight at 37°C. When required, lipopolysaccharide (LPS) stimulation was performed for 3 hours at 1 µg/mL, followed by 30 minutes of incubation in the presence of 5 mmol/L ATP. Cytokine detection. The levels of murine cytokines (IL-1, IL-1, tumor necrosis factor [TNF], and IL-6) were measured by specific enzyme-linked immunosorbent assay (ELISA) kits (Genzyme, Cambridge, MA), following the manufacturer's instructions, on the supernatants of the 30-minute ATP stimulation. When necessary, the same peritoneal macrophage supernatants were used for the simultaneous detection of the four cytokines. The drugs were added at the indicated concentrations during the 30 minutes of ATP incubation. Each experimental point was assessed on four individual wells. Preparation of human monocytes and assessment of cytokine release by Western blotting. Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats from healthy donors by Ficoll-Hypaque gradients, resuspended at 107/mL in RPMI medium containing 10% FCS, and plated as described.2 After 1 hour at 37°C, nonadherent cells were removed and adherent cells were activated for 1 hour with 5 µg/mL LPS (Sigma, St Louis, MO) in RPMI/FCS. Supernatants were then replaced with RPMI 1% Nutridoma (Boehringer Mannheim, Mannheim, Germany) and incubation was performed for additional 30 minutes in the presence of 1 mmol/L ATP or 4 hours in the absence of ATP.16 At the end of incubation, supernatants were concentrated by precipitation with 10% trichloroacetic acid (TCA) and cells were lysed in 0.25% NP40. Aliquots of cell lysates and supernatants were boiled in Laemmli sample buffer containing 2 mercaptoethanol (2ME), resolved by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and blotted to Hybond-ECL (Amersham International, Little Chalfont, UK), as described.17 Blots were probed with anti-IL-1 monoclonal antibody 3ZD or with the polyclonal goat anti-IL-6 (generous gift of F. Cozzolino, Rome, Italy), followed by peroxidase-conjugated secondary antibody (Dakopatts, Glostrup, Denmark) and developed with the ECL system (Amersham) following the manufacturer's instructions. Oocytes preparation. Stage V Xenopus laevis oocytes were prepared and injected with ABC1 encoding cRNA or water as previously described in detail.12 Each batch of oocytes was tested for faithful expression of ABC1 transporter by immunoprecipitation with anti-ABC1 specific antibody. Iodide efflux measurements. The procedure for I125 efflux measurements from X oocytes is described in detail in Becq et al.12 For peritoneal macrophages, the procedure is essentially as described in Becq et al.18 Briefly, macrophages cultured overnight in complete medium in 48-well plates were washed twice in modified Earle's salt solution (ESS) and loaded with 1 mL of 1 µmol/L KI (0.1 µCi/mL of NaI125 ) in ESS for 30 minutes at 37°C. After a few washes to achieve equilibration, the amount of radioactive iodide in the efflux medium was measured at 1-minute intervals for 11 minutes. The first two points were used to establish a stable efflux baseline. At the end of incubation (t8), the medium was recovered and the amount of cell associated radioactivity was counted after lysis of the monolayers in 1 N NaOH. The drugs to be tested were dissolved in dimethyl sulfoxide (DMSO; final concentration, 0.1%) and added during the ATP incubation and the efflux washes. For both oocytes and macrophages experiments, efflux curves were generated by plotting the percentage of total radioactivity released for each time point versus time. Data are presented as the mean ± SD for n observations. Statistical significance is assessed at the 95% confidence level with the Student's t-test. Chemicals. Glyburide, 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), sulphobromophtaleine (BSP), and ATP were purchased from Sigma; Tenidap and UK5099 were provided by Pfizer (Grotow, CT); and the peptide inhibitor of ICE, AcYVAD-chloromethylketone, was purchased from Bachem Biochemica (Bubendorf, CH). When necessary, the compounds were dissolved in DMSO and used at a final DMSO concentration never exceeding 0.1%. LPS (Escherichia coli strain 0111:B4) was purchased from Calbiochem (La Jolla, CA).     RESULTS Abstract Introduction Methods Results Discussion References Glyburide blocks IL-1 secretion from mouse macrophages and human monocytes. Thioglycollate-elicited mouse peritoneal macrophages were stimulated with LPS (1 µg/mL for 3 hours) and ATP (5 mmol/L for 30 minutes) in the presence of increasing concentrations of glyburide (1, 10, or 100 µmol/L), and the amount of IL-1 recovered in the supernatant of the ATP incubation was measured by ELISA (Fig 1A). The results showed that glyburide induces a dose-dependent reduction of IL-1 secretion. To control the specificity of this effect, the supernatants at the most effective doses were used to measure the secretion of IL-1, which also leaves the cells via unusual mechanisms, and of TNF and IL-6, which are exocytosed by the classical ER-Golgi pathway.19 In each experiment, four individual samples were measured and averaged for each experimental point. As shown in Fig 1B, glyburide treatment leaves almost unaffected the amounts of secreted IL-1 (n = 4), TNF (n = 6), or IL-6 (n = 4). View larger version (22K): [in this window] [in a new window]   Fig 1. Glyburide inhibits the secretion of IL-1 from mouse peritoneal macrophages without affecting the release of IL-1, TNF, or IL-6. (A) Dose-dependent inhibition of IL-1 release from macrophage monolayers as assessed by ELISA. Results are averaged from four individual assays and expressed as a percentage of release in the absence of the drug. Absolute values in picograms per milliliter are indicated. (B) Comparative effect of 100 µmol/L glyburide on the secretion of IL-1 IL-1, TNF, or IL-6. Results (averaged from 6 experiments for IL-1 and TNF and from 4 for IL-1 and IL-6) are expressed as a percentage of the amount released in the absence of drug. Similar experiments were performed on metabolically labeled cells and the analysis of immunoprecipitated IL-1 showed no effect of glyburide on the intracellular amounts of the cytokine, whereas the recovery of extracellular 17-kD IL-1 mirrored the results of the ELISA (not shown). Glyburide exerts a similar inhibition on IL-1 secretion from activated human monocytes, as assessed by Western blot analysis, both after long-term LPS stimulation or after ATP enhancement (Fig 2A and B). As already reported,1 extracellular IL-1 was undetectable in both conditions (not shown). No modifications on IL-6 secretion were detected after treatment with glyburide (Fig 2C). View larger version (24K): [in this window] [in a new window]   Fig 2. Glyburide inhibits IL-1 release from human monocytes without affecting the processing. Cell lysates (cyt) and supernatants (sup) from untreated human activated monocytes (U) or cells exposed to Glyburide (G; 100 µmol/L) were analyzed using Western blotting and probed with an anti-IL-1 specific antibody ([A] after LPS and ATP stimulation and [B] after long-term LPS stimulation). Reduced amounts of the 17-kD mature form of IL-1 are recovered in the supernatants of treated cells in the absence of a detectable difference in the intracellular profiles. In (C), the absence of effect of glyburide on the secretion of IL-6 is shown. In (D), supernatants from human activated monocytes either untreated (U) or treated with 100 µmol/L glyburide (G) or 100 µmol/L AcYVAD-CHO or both were analyzed using Western blotting. Whereas AcYVAD treatment leads to extracellular accumulation of proIL-1 and blocks its processing to the mature form, the treatment with glyburide clearly impairs the recovery of the precursor both in the absence and in the presence of ICE inhibitors. Glyburide had no effect on the activity of recombinant human ICE in vitro (not shown), thus ruling out the possibility that the reduced recovery of the 17-kD IL-1 resulted from pharmacologic interference with ICE-mediated processing. In addition, we compared the molecular forms of IL-1 secreted by monocytes treated with acYVAD-CHO, as a specific inhibitor of ICE,20 in the presence or absence of glyburide (100 µmol/L). As shown in Fig 2D, the treatment with acYVAD-CHO leads to the accumulation in the extracellular medium of the unprocessed 33-kD proIL-1 form21; this accumulation is effectively prevented by glyburide treatment. The anion transporter activity of ABC1 and IL-1 secretion are affected by the same drugs. As already reported, the expression of ABC1 transporter in X oocytes generates a specific anion efflux that can be inhibited in a dose-dependent fashion by glyburide and other compounds belonging to different pharmacologic classes, such as DIDS and BSP (inhibition of 88%, 84%, and 79%, respectively).12 We therefore analyzed the effect of the latter compounds on the secretion of IL-1, IL-1, TNF, or IL-6. Figure 3A and B shows that these ABC1 blockers also inhibit IL-1 secretion while only marginally affecting the secretion of the other cytokines. On the contrary, the classical MDR reversal agent verapamil had no effect on the secretion of IL-1 (data not shown). These data indicate a clear pharmacologic correlation between ABC1 activity and IL-1 secretion. View larger version (15K): [in this window] [in a new window]   Fig 3. (A) The ABC1 blockers, DIDS and BSP, inhibit the secretion of IL-1 in a dose-dependent fashion. Results are expressed as a percentage of the secretion from untreated macrophage monolayers. Absolute amounts (average from 4 individual points) of IL-1 in picograms per milliliter are reported. (B) Comparative effect of DIDS and BSP on the secretion of IL-1, IL-1, TNF, or IL-6. Results (averaged from 6 experiments for IL-1 and TNF and from 4 for IL-1 and IL-6) are expressed as a percentage of the amount released in the absence of drug. We then tested the effect on ABC1 activity of two anti-inflammatory agent, Tenidap and UK 5099, known to reduce IL-1 secretion possibly via the perturbation of anionic fluxes that they provoke.15 Both drugs show a dose-dependent inhibition of the ABC1-mediated anion efflux from X oocytes (maximal inhibition at 100 µmol/L; data not shown). To investigate the activity of ABC1 in cells physiologically expressing the transporter, we investigated the anion efflux from ex vivo peritoneal macrophages in basal conditions and after LPS/ATP stimulation.16,22,23 An anion efflux of 51.7% ± 6.1% (n = 16) can be detected at t8 in basal conditions, and this is increased to 67.7% ± 6.6% (n = 20) after LPS/ATP stimulation. We then tested the effect of the various drugs on the basal and induced anion flux. Our data showed that a fraction of this efflux, which increases after stimulation, is sensitive to the panel of compounds. In fact, in basal conditions, efflux values at t8 were 33% ± 1% (n = 2) in the presence of DIDS (500 µmol/L); 42% ± 2% (n = 2) in the presence of BSP (500 µmol/L); and 49% ± 1% (n = 2) in the presence of glyburide (100 µmol/L). After stimulation with LPS and ATP, DIDS reduces the efflux to 32.5% ± 3% (n = 6), BSP to 46.8% ± 2% (n = 3), and glyburide to 35.7% ± 12% (n = 3). In these conditions, the incubation with Tenidap (200 µmol/L) and UK5099 (100 µmol/L) reduces anion effluxes to 44.6% ± 5% (n = 5) and 46% ± 6% (n = 2). All the compounds are inhibitory in a dose-dependent fashion, as shown in Fig 4A through C. We concluded from these results that, in mouse peritoneal macrophages, a fraction of the anion effluxes is dependent from the activity of ABC1 transporter. View larger version (18K): [in this window] [in a new window]   Fig 4. Sensitivity profile of anion fluxes from mouse peritoneal macrophages to DIDS and BSP (A), Tenidap and UK5099 (B), and Glyburide (C). I125 efflux was measured in the presence of the indicated concentrations of drugs from cells stimulated by LPS/ATP and in basal conditions. The difference between the flux in the absence of the drug from stimulated and unstimulated cells was considered the reference value. The effect of the drug is reported as a percentage of the reference flux. Absolute values are reported below each panel.     DISCUSSION Abstract Introduction Methods Results Discussion References In this report, we show that glyburide is a potent inhibitor of the secretion of the leaderless cytokine IL-1. The inhibition is selective, because secretion via the classical exocytic pathway is not impaired and is devoid of toxic effect, because macrophage viability and the rate of protein synthesis are unaffected. We have previously reported that glyburide is one of the inhibitors of the anion exchanger activity of the ABC transporter, ABC1, in the heterologous expression system of X oocytes.16 The data presented here show a precise correlation between the pharmacologic inhibition of the ABC1 activity and of the secretion of IL-1. Indeed, in addition to glyburide, BSP and DIDS also inhibit both ABC1 and IL-1 secretion. In turn, two other compounds known to affect IL-1 secretion also inhibit ABC1. The finding that ABC1 exerts a detectable anion exchanger function in the physiologic system of mouse peritoneal macrophages and that, in these cells, both IL-1 secretion and ABC1 activity are impaired by the same drugs suggests the involvement of ABC1 in IL-1 secretion. The hypothesis that a member of the ABC transporter family may play a role in leaderless secretion in mammals arises from the evidence of their involvement in analogous pathways both in yeast and procaryotes. However, experiments trying to unambiguously demonstrate a direct involvement have failed so far. Moreover, drugs able to inhibit the activity of known ABC transporters such as MDR do not affect IL-1 secretion (A.R. and M.F.L., unpublished result). This is in line with our observation that ABC1 sensitivity profile is original among ABC transporters, because verapamil, a typical MDR reversing agent, does not affect ABC1 function; conversely, cystic fibrosis transmembrane regulator (CFTR) is insensitive to the ABC1 inhibitor DIDS. Although glyburide sensitivity is not exclusive to ABC1 but it is shared by CFTR and sulfonylurea receptor (SUR), the involvement of CFTR can be ruled out due to its DIDS insensitivity, whereas SUR involvement is unlikely because of its different sensitivity to glyburide and its barely detectable expression in cells of the macrophage lineage.24 Whereas glyburide profoundly affects IL-1 secretion, it only sligthly decreases, in the mouse system, the release of IL-1, another leaderless secretory protein. Whether this means that IL-1 follows a distinct route remains to be elucidated. However, it is of note that, at least in the human system, IL-1 is the major secreted form, with IL-1 being almost undetectable extracellularly. The molecular mechanism underlying the inhibitory effect of ABC1 blockers on IL-1 secretion is still unclear. However, the reduced secretion of IL-1 did not result from altered synthesis or increased instability of intracellular pools, because the treatment with these drugs did not modify the amounts of the intracellular cytokine. Moreover, we could exclude any effect of glyburide on the processing of the precursor by ICE. Indeed, glyburide shows no inhibitory effect on recombinant ICE in vitro and prevents the extracellular accumulation of proIL-1 induced by ICE inhibitors. Our data support the hypothesis that proIL-1 is a secretory competent form and imply that the molecular step affected by ABC1 inhibitory drugs is dissociated from the proteolytic maturation of IL-1. Thus, our results allow to surmize an implication of ABC1 or a closely related transporter in the alternative secretory pathway for the export of the cytokine. Whether this transporter is indeed the channel through which IL-1 translocates the membrane or fulfills a permissive role for the process to take place remains to be investigated.     FOOTNOTES    Submitted May 28, 1997; accepted July 28, 1997.    Supported by institutional grants from INSERM and CNRS and specific grants from ARC, AIRC, and LLNC. F.B. was supported by a postdoctoral fellowship from AFLM.    Address reprint requests to Giovanna Chimini, MD, Centre d'Immunologie de Marseille-Luminy, Parc Scientifique de Luminy, Case 906, 13288 Marseille Cedex 09, France.    The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hearly marked ``advertisment'' in accordance with 18 U.S.C. section 1734 solely to indicate this fact.     ACKNOWLEDGMENT The authors thank A. Diu-Hercend and O. Krebs (Roussel-Uclaf ) for testing the effects of glyburide, DIDS, and BSP on recombinant human ICE; C. Gabel (Pfizer Inc) for discussion and for having provided Tenidap and UK5099; F. Cozzolino for the anti-IL-6 antiserum; C. Reynolds for the 3ZD antibody; and B. Verrier and M. Gola for discussion. The Centro Trasfusionale of Gaslini Hospital (Genova, Italy) is also thanked for the generous gift of buffy coats.     REFERENCES Abstract Introduction Methods Results Discussion References 1. Dinarello CA: Biological Basis for Interleukin-1 in Disease. Blood 87:2095, 1996[Abstract/Free Full Text] 2. Rubartelli A, Cozzolino F, Talio M, Sitia R: A novel secretory pathway for interleukin-1, a protein lacking a signal sequence. EMBO J 9:1503, 1990[Medline] [Order article via Infotrieve] 3. Muesch A, Hartmann E, Rohde K, Rubartelli A, Sitia R, Rapoport TA: A novel pathway for secretory proteins? Trends Biochem Sci 15:86, 1990[Medline] [Order article via Infotrieve] 4. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan JY: Human ICE/CED-3 protease nomenclature. Cell 87:171, 1996[Medline] [Order article via Infotrieve] 5. Li P, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskind M, Rodman L, Salfeld J, Towne E, Tracey D, Wardwell S, Wei F-Y, Wong W, Kamen R, Seshadri T: Mice deficient in IL-1beta-convering enzyme are defective in production of mature IL-1beta and resistant to endotoxic shock. Cell 80:401, 1995[Medline] [Order article via Infotrieve] 6. Miossec C, Decoen MC, Fassy F, Diu-Hercend A: Use of monoclonal antibodies to study IL-1 converting enzyme expression: Only precursor forms are detected in IL-1 secreting cells. Eur J Immunol 26:1032, 1996[Medline] [Order article via Infotrieve] 7. Singer II, Scott S, Chin J, Bayne EK, Limjuco G, Weidner J, Miller DK, Chapman K, Kostura MJ: The interleukin-1-converting enzyme (ICE) is localized on the external cell surface membranes and in the cytoplasmic ground substance of the human monocytes by immuno-electron microscopy. J Exp Med 182:1447, 1995[Abstract/Free Full Text] 8. Kuchler K, Rubartelli A, Holland B (eds): Unusual Secretory Pathways: From Bacteria to Man. Austin, TX, Landes Bioscience, 1997 9. Higgins CF: ABC transporters: From microorganisms to man. Annu Rev Cell Biol 8:67, 1992 10. Luciani MF, Denizot F, Savary S, Mattei MG, Chimini G: Cloning of two novel ABC transporters mapping on human chromosome 9. Genomics 21:150, 1994[Medline] [Order article via Infotrieve] 11. Luciani MF, Chimini G: The ATP binding cassette transporter ABC1, is required for the engulfment of corpses generated by apoptoic cell death. EMBO J 15:226, 1996[Medline] [Order article via Infotrieve] 12. Becq F, Hamon Y, Bajetto A, Gola M, Verrier B, Chimini G: ABC1, an ATP binding cassette transporter required during apoptosis, generates a regulated anion flux after expression in Xenopus oocytes. J Biol Chem 272:2695, 1997[Abstract/Free Full Text] 13. Perregaux DG, Svensson L, Gabel CA: Tenidap and other anion inhibitors disrupt cytosolic T lymphocyte-mediated IL-1 post-translational processing. J Immunol 157:57, 1996[Abstract] 14. McNiff P, Svensson L, Pazoles CJ, Gabel CA: Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. I. Mechanisms and evidence of functional significance. J Immunol 153:2180, 1994[Abstract] 15. Laliberte R, Perregaux D, Pazoles CJ, Gabel CA: Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. II. Inhibition of IL1beta production from ATP-treated monocytes and macrophages. J Immunol 153:2168, 1994[Abstract] 16. Rubartelli A, Bajetto A, Allavena G, Cozzolino F, Sitia R: Post-translational regulation of interleukin 1 secretion. Cytokine 5:117, 1993[Medline] [Order article via Infotrieve] 17. Rubartelli A, Bonifaci N, Sitia R: High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells. Cancer Res 55:675, 1995[Abstract/Free Full Text] 18. Becq F, Verrier B, Chang XB, Riordan JR, Hanrahan JW: cAMP- and Ca2+-independent activation of cystic fibrosis transmembrane conductance regulator channels by phenylimidazothiazole drugs. J Biol Chem 271:16171, 1996[Abstract/Free Full Text] 19. Kriegler M, Perez C, DeFay K, Albert L, Lu SD: A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53:45, 1988[Medline] [Order article via Infotrieve] 20. Henkart PA: ICE family proteases: Mediators of all apoptotic cell death? Immunity 4:195, 1996[Medline] [Order article via Infotrieve] 21. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, Elliston KO, Ayala JM, Casano F, Chin J, Ding GJ-F, Egger LA, Gaffney EP, Limjuco G, Palyha O, Raju SM, Rolando AM, Salley JP, Yamin T-T, Lee TD, Shively JE, MacCross M, Mumford RA, Schmidt JA, Tocci MJ: A novel heterodimeric cysteine protease is required for interleukin-1beta processing in monocytes. Nature 356:768, 1992[Medline] [Order article via Infotrieve] 22. Perregaux DG, Gabel CA: IL1beta maturation and release in response to ATP and nigericin. J Biol Chem 269:15195, 1994[Abstract/Free Full Text] 23. Hogquist KA, Nett MA, Unanue ER, Chaplin DD: Interleukin 1 is processed and released during apoptosis. Proc Natl Acad Sci USA 88:8485, 1991[Abstract/Free Full Text] 24. Schultz BD, De Roos AD, Venglarik CJ, Singh AK, Frizzell RA, Bridges RJ: Glibenclamide blockade of CFTR chloride channels. Am J Physiol 271:L192, 1996 © 1997 by The American Society of Hematology. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Lamkanfi, J. L. Mueller, A. C. Vitari, S. Misaghi, A. Fedorova, K. Deshayes, W. P. Lee, H. M. Hoffman, and V. M. Dixit Glyburide inhibits the Cryopyrin/Nalp3 inflammasome J. Cell Biol., October 5, 2009; 187(1): 61 - 70. [Abstract] [Full Text] [PDF] U. Martin, J. Scholler, J. Gurgel, B. Renshaw, J. E. Sims, and C. A. Gabel Externalization of the Leaderless Cytokine IL-1F6 Occurs in Response to Lipopolysaccharide/ATP Activation of Transduced Bone Marrow Macrophages J. Immunol., September 15, 2009; 183(6): 4021 - 4030. [Abstract] [Full Text] [PDF] R. Das, T. Burke, D. R. Van Wagoner, and E. F. Plow L-Type Calcium Channel Blockers Exert an Antiinflammatory Effect by Suppressing Expression of Plasminogen Receptors on Macrophages Circ. Res., July 17, 2009; 105(2): 167 - 175. [Abstract] [Full Text] [PDF] M. Merk, J. Baugh, S. Zierow, L. Leng, U. Pal, S. J. Lee, A. D. Ebert, Y. Mizue, J. O. Trent, R. Mitchell, et al. The Golgi-Associated Protein p115 Mediates the Secretion of Macrophage Migration Inhibitory Factor J. Immunol., June 1, 2009; 182(11): 6896 - 6906. [Abstract] [Full Text] [PDF] P. J. Mintz, M. Cardo-Vila, M. G. Ozawa, A. Hajitou, R. Rangel, L. Guzman-Rojas, D. R. Christianson, M. A. Arap, R. J. Giordano, G. R. Souza, et al. An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment PNAS, February 17, 2009; 106(7): 2182 - 2187. [Abstract] [Full Text] [PDF] D. F. P. Leite, J. Echevarria-Lima, S. C. Ferreira, J. B. Calixto, and V. M. Rumjanek ABCC transporter inhibition reduces zymosan-induced peritonitis J. Leukoc. Biol., September 1, 2007; 82(3): 630 - 637. [Abstract] [Full Text] [PDF] Y. Qu, L. Franchi, G. Nunez, and G. R. Dubyak Nonclassical IL-1beta Secretion Stimulated by P2X7 Receptors Is Dependent on Inflammasome Activation and Correlated with Exosome Release in Murine Macrophages J. Immunol., August 1, 2007; 179(3): 1913 - 1925. [Abstract] [Full Text] [PDF] K. Balasubramanian, B. Mirnikjoo, and A. J. Schroit Regulated Externalization of Phosphatidylserine at the Cell Surface: IMPLICATIONS FOR APOPTOSIS J. Biol. Chem., June 22, 2007; 282(25): 18357 - 18364. [Abstract] [Full Text] [PDF] Y. Ikeda, A. Murakami, Y. Fujimura, H. Tachibana, K. Yamada, D. Masuda, K.-i. Hirano, S. Yamashita, and H. Ohigashi Aggregated Ursolic Acid, a Natural Triterpenoid, Induces IL-1beta Release from Murine Peritoneal Macrophages: Role of CD36 J. Immunol., April 15, 2007; 178(8): 4854 - 4864. [Abstract] [Full Text] [PDF] D. Brough and N. J. Rothwell Caspase-1-dependent processing of pro-interleukin-1beta is cytosolic and precedes cell death J. Cell Sci., March 1, 2007; 120(5): 772 - 781. [Abstract] [Full Text] [PDF] S. S. Mambula and S. K. Calderwood Heat Shock Protein 70 Is Secreted from Tumor Cells by a Nonclassical Pathway Involving Lysosomal Endosomes J. Immunol., December 1, 2006; 177(11): 7849 - 7857. [Abstract] [Full Text] [PDF] A. Daryadel, R. F. Grifone, H.-U. Simon, and S. Yousefi Apoptotic Neutrophils Release Macrophage Migration Inhibitory Factor upon Stimulation with Tumor Necrosis Factor-{alpha} J. Biol. Chem., September 15, 2006; 281(37): 27653 - 27661. [Abstract] [Full Text] [PDF] A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF] E. Naschberger, C. Lubeseder-Martellato, N. Meyer, R. Gessner, E. Kremmer, A. Gessner, and M. Sturzl Human Guanylate Binding Protein-1 Is a Secreted GTPase Present in Increased Concentrations in the Cerebrospinal Fluid of Patients with Bacterial Meningitis Am. J. Pathol., September 1, 2006; 169(3): 1088 - 1099. [Abstract] [Full Text] [PDF] R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF] S. Omer, D. Meredith, J. F. Morris, and H. C. Christian Evidence for the Role of Adenosine 5'-Triphosphate-Binding Cassette (ABC)-A1 in the Externalization of Annexin 1 from Pituitary Folliculostellate Cells and ABCA1-Transfected Cell Models Endocrinology, July 1, 2006; 147(7): 3219 - 3227. [Abstract] [Full Text] [PDF] P. A. Verhoef, S. B. Kertesy, K. Lundberg, J. M. Kahlenberg, and G. R. Dubyak Inhibitory Effects of Chloride on the Activation of Caspase-1, IL-1{beta} Secretion, and Cytolysis by the P2X7 Receptor J. Immunol., December 1, 2005; 175(11): 7623 - 7634. [Abstract] [Full Text] [PDF] J. F. Oram and J. W. Heinecke ATP-Binding Cassette Transporter A1: A Cell Cholesterol Exporter That Protects Against Cardiovascular Disease Physiol Rev, October 1, 2005; 85(4): 1343 - 1372. [Abstract] [Full Text] [PDF] C. Albrecht, J. H. McVey, J. I. Elliott, A. Sardini, I. Kasza, A. D. Mumford, R. P. Naoumova, E. G. D. Tuddenham, K. Szabo, and C. F. Higgins A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome Blood, July 15, 2005; 106(2): 542 - 549. [Abstract] [Full Text] [PDF] J. M. Coutinho, R. R. Singaraja, M. Kang, D. J. Arenillas, L. N. Bertram, N. Bissada, B. Staels, J.-C. Fruchart, C. Fievet, A. M. Joseph-George, et al. Complete functional rescue of the ABCA1-/- mouse by human BAC transgenesis J. Lipid Res., June 1, 2005; 46(6): 1113 - 1123. [Abstract] [Full Text] [PDF] S Soumian, C Albrecht, A. Davies, and R. Gibbs ABCA1 and atherosclerosis Vascular Medicine, May 1, 2005; 10(2): 109 - 119. [Abstract] [PDF] S. M. Bared, C. Buechler, A. Boettcher, R. Dayoub, A. Sigruener, M. Grandl, C. Rudolph, A. Dada, and G. Schmitz Association of ABCA1 with Syntaxin 13 and Flotillin-1 and Enhanced Phagocytosis in Tangier Cells Mol. Biol. Cell, December 1, 2004; 15(12): 5399 - 5407. [Abstract] [Full Text] [PDF] N. Amzallag, B. J. Passer, D. Allanic, E. Segura, C. Thery, B. Goud, R. Amson, and A. Telerman TSAP6 Facilitates the Secretion of Translationally Controlled Tumor Protein/Histamine-releasing Factor via a Nonclassical Pathway J. Biol. Chem., October 29, 2004; 279(44): 46104 - 46112. [Abstract] [Full Text] [PDF] A. Dani, A. Chaudhry, P. Mukherjee, D. Rajagopal, S. Bhatia, A. George, V. Bal, S. Rath, and S. Mayor The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment J. Cell Sci., August 15, 2004; 117(18): 4219 - 4230. [Abstract] [Full Text] [PDF] A. Rouhiainen, J. Kuja-Panula, E. Wilkman, J. Pakkanen, J. Stenfors, R. K. Tuominen, M. Lepantalo, O. Carpen, J. Parkkinen, and H. Rauvala Regulation of monocyte migration by amphoterin (HMGB1) Blood, August 15, 2004; 104(4): 1174 - 1182. [Abstract] [Full Text] [PDF] T. J. F. Nieland, A. Chroni, M. L. Fitzgerald, Z. Maliga, V. I. Zannis, T. Kirchhausen, and M. Krieger Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide J. Lipid Res., July 1, 2004; 45(7): 1256 - 1265. [Abstract] [Full Text] [PDF] R. Backhaus, C. Zehe, S. Wegehingel, A. Kehlenbach, B. Schwappach, and W. Nickel Unconventional protein secretion: membrane translocation of FGF-2 does not require protein unfolding J. Cell Sci., May 1, 2004; 117(9): 1727 - 1736. [Abstract] [Full Text] [PDF] R. Sluyter, A. N. Shemon, and J. S. Wiley Glu496 to Ala Polymorphism in the P2X7 Receptor Impairs ATP-Induced IL-1{beta} Release from Human Monocytes J. Immunol., March 15, 2004; 172(6): 3399 - 3405. [Abstract] [Full Text] [PDF] T. Schafer, H. Zentgraf, C. Zehe, B. Brugger, J. Bernhagen, and W. Nickel Unconventional Secretion of Fibroblast Growth Factor 2 Is Mediated by Direct Translocation across the Plasma Membrane of Mammalian Cells J. Biol. Chem., February 20, 2004; 279(8): 6244 - 6251. [Abstract] [Full Text] [PDF] A. Colomar, V. Marty, C. Medina, C. Combe, P. Parnet, and T. Amedee Maturation and Release of Interleukin-1{beta} by Lipopolysaccharide-primed Mouse Schwann Cells Require the Stimulation of P2X7 Receptors J. Biol. Chem., August 15, 2003; 278(33): 30732 - 30740. [Abstract] [Full Text] [PDF] L. Gudipaty, J. Munetz, P. A. Verhoef, and G. R. Dubyak Essential role for Ca2+ in regulation of IL-1{beta} secretion by P2X7 nucleotide receptor in monocytes, macrophages, and HEK-293 cells Am J Physiol Cell Physiol, August 1, 2003; 285(2): C286 - C299. [Abstract] [Full Text] [PDF] P. A. Verhoef, M. Estacion, W. Schilling, and G. R. Dubyak P2X7 Receptor-Dependent Blebbing and the Activation of Rho-Effector Kinases, Caspases, and IL-1{beta} Release J. Immunol., June 1, 2003; 170(11): 5728 - 5738. [Abstract] [Full Text] [PDF] J. F. Oram HDL Apolipoproteins and ABCA1: Partners in the Removal of Excess Cellular Cholesterol Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 720 - 727. [Abstract] [Full Text] [PDF] M. Tanudji, S. Hevi, and S. L. Chuck The nonclassic secretion of thioredoxin is not sensitive to redox state Am J Physiol Cell Physiol, May 1, 2003; 284(5): C1272 - C1279. [Abstract] [Full Text] [PDF] L. P. Chapman, M. J. Epton, J. C. Buckingham, J. F. Morris, and H. C. Christian Evidence for a Role of the Adenosine 5'-Triphosphate-Binding Cassette Transporter A1 in the Externalization of Annexin I from Pituitary Folliculo-Stellate Cells Endocrinology, March 1, 2003; 144(3): 1062 - 1073. [Abstract] [Full Text] [PDF] O. MASMOUDI, P. GANDOLFO, J. LEPRINCE, D. VAUDRY, A. FOURNIER, C. PATTE-MENSAH, H. VAUDRY, and M.-C. TONON Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates endozepine release from cultured rat astrocytes via a PKA-dependent mechanism FASEB J, January 1, 2003; 17(1): 17 - 27. [Abstract] [Full Text] [PDF] L. Chapman, A. Nishimura, J. C. Buckingham, J. F. Morris, and H. C. Christian Externalization of Annexin I from A Folliculo-Stellate-Like Cell Line Endocrinology, November 1, 2002; 143(11): 4330 - 4338. [Abstract] [Full Text] [PDF] S. T. Reddy, S. Hama, C. Ng, V. Grijalva, M. Navab, and A. M. Fogelman ATP-Binding Cassette Transporter 1 Participates in LDL Oxidation by Artery Wall Cells Arterioscler Thromb Vasc Biol, November 1, 2002; 22(11): 1877 - 1883. [Abstract] [Full Text] [PDF] J. W. Burgess, R. S. Kiss, H. Zheng, S. Zachariah, and Y. L. Marcel Trypsin-sensitive and Lipid-containing Sites of the Macrophage Extracellular Matrix Bind Apolipoprotein A-I and Participate in ABCA1-dependent Cholesterol Efflux J. Biol. Chem., August 23, 2002; 277(35): 31318 - 31326. [Abstract] [Full Text] [PDF] G. Hasko, E. A. Deitch, Z. H. Nemeth, D. G. Kuhel, and C. Szabo Inhibitors of ATP-Binding Cassette Transporters Suppress Interleukin-12 p40 Production and Major Histocompatibility Complex II Up-Regulation in Macrophages J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 103 - 110. [Abstract] [Full Text] [PDF] R. J. Aiello, D. Brees, P.-A. Bourassa, L. Royer, S. Lindsey, T. Coskran, M. Haghpassand, and O. L. Francone Increased Atherosclerosis in Hyperlipidemic Mice With Inactivation of ABCA1 in Macrophages Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 630 - 637. [Abstract] [Full Text] [PDF] D. G. Perregaux, K. Bhavsar, L. Contillo, J. Shi, and C. A. Gabel Antimicrobial Peptides Initiate IL-1{beta} Posttranslational Processing: A Novel Role Beyond Innate Immunity J. Immunol., March 15, 2002; 168(6): 3024 - 3032. [Abstract] [Full Text] [PDF] F. Leoni, A. Zaliani, G. Bertolini, G. Porro, P. Pagani, P. Pozzi, G. Dona, G. Fossati, S. Sozzani, T. Azam, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines PNAS, February 20, 2002; (2002) 52702999. [Abstract] [Full Text] [PDF] D. G. Perregaux, P. McNiff, R. Laliberte, N. Hawryluk, H. Peurano, E. Stam, J. Eggler, R. Griffiths, M. A. Dombroski, and C. A. Gabel Identification and Characterization of a Novel Class of Interleukin-1 Post-Translational Processing Inhibitors J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 187 - 197. [Abstract] [Full Text] [PDF] A. VON ECKARDSTEIN, C. LANGER, T. ENGEL, I. SCHAUKAL, A. CIGNARELLA, J. REINHARDT, S. LORKOWSKI, Z. LI, X. ZHOU, P. CULLEN, et al. ATP binding cassette transporter ABCA1 modulates the secretion of apolipoprotein E from human monocyte-derived macrophages FASEB J, July 1, 2001; 15(9): 1555 - 1561. [Abstract] [Full Text] [PDF] R. M. Lawn, D. P. Wade, T. L. Couse, and J. N. Wilcox Localization of Human ATP-Binding Cassette Transporter 1 (ABC1) in Normal and Atherosclerotic Tissues Arterioscler Thromb Vasc Biol, March 1, 2001; 21(3): 378 - 385. [Abstract] [Full Text] [PDF] A. von Eckardstein, J.-R. Nofer, and G. Assmann High Density Lipoproteins and Arteriosclerosis : Role of Cholesterol Efflux and Reverse Cholesterol Transport Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 13 - 27. [Abstract] [Full Text] [PDF] S. Gardella, C. Andrei, S. Costigliolo, L. Olcese, M. R. Zocchi, and A. Rubartelli Secretion of bioactive interleukin-1beta by dendritic cells is modulated by interaction with antigen specific T cells Blood, June 15, 2000; 95(12): 3809 - 3815. [Abstract] [Full Text] [PDF] I. Walev, J. Klein, M. Husmann, A. Valeva, S. Strauch, H. Wirtz, O. Weichel, and S. Bhakdi Potassium Regulates IL-1{beta} Processing Via Calcium-Independent Phospholipase A2 J. Immunol., May 15, 2000; 164(10): 5120 - 5124. [Abstract] [Full Text] [PDF] R. E. Laliberte, J. Eggler, and C. A. Gabel ATP Treatment of Human Monocytes Promotes Caspase-1 Maturation and Externalization J. Biol. Chem., December 24, 1999; 274(52): 36944 - 36951. [Abstract] [Full Text] [PDF] C. Andrei, C. Dazzi, L. Lotti, M. R. Torrisi, G. Chimini, and A. Rubartelli The Secretory Route of the Leaderless Protein Interleukin 1beta Involves Exocytosis of Endolysosome-related Vesicles Mol. Biol. Cell, May 1, 1999; 10(5): 1463 - 1475. [Abstract] [Full Text] D. G. Perregaux and C. A. Gabel Human monocyte stimulus-coupled IL-1beta posttranslational processing: modulation via monovalent cations Am J Physiol Cell Physiol, December 1, 1998; 275(6): C1538 - C1547. [Abstract] [Full Text] [PDF] M. Solle, J. Labasi, D. G. Perregaux, E. Stam, N. Petrushova, B. H. Koller, R. J. Griffiths, and C. A. Gabel Altered Cytokine Production in Mice Lacking P2X7 Receptors J. Biol. Chem., January 5, 2001; 276(1): 125 - 132. [Abstract] [Full Text] [PDF] L. B. Cavelier, Y. Qiu, J. K. Bielicki, V. Afzal, J.-F. Cheng, and E. M. Rubin Regulation and Activity of the Human ABCA1 Gene in Transgenic Mice J. Biol. Chem., May 18, 2001; 276(21): 18046 - 18051. [Abstract] [Full Text] [PDF] G. Angelini, S. Gardella, M. Ardy, M. R. Ciriolo, G. Filomeni, G. Di Trapani, F. Clarke, R. Sitia, and A. Rubartelli From the Cover: Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation PNAS, February 5, 2002; 99(3): 1491 - 1496. [Abstract] [Full Text] [PDF] F. Leoni, A. Zaliani, G. Bertolini, G. Porro, P. Pagani, P. Pozzi, G. Dona, G. Fossati, S. Sozzani, T. Azam, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines PNAS, March 5, 2002; 99(5): 2995 - 3000. [Abstract] [Full Text] [PDF] R. J. Aiello, D. Brees, P.-A. Bourassa, L. Royer, S. Lindsey, T. Coskran, M. Haghpassand, and O. L. Francone Increased Atherosclerosis in Hyperlipidemic Mice With Inactivation of ABCA1 in Macrophages Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 630 - 637. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hamon, Y. Articles by Chimini, G. Search for Related Content PubMed PubMed Citation Articles by Hamon, Y. Articles by Chimini, G. Social Bookmarking                   What's this?

	Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020